Acelot, Inc

Acelot, Inc., based in Santa Barbara, CA, pioneers a new approach to developing small molecules for challenging targets in diseases with high unmet needs. The company's lead program focuses on targeting TDP-43 to treat amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. TDP-43, a critical protein in cellular activities, plays a significant role in ALS progression by leading to the death of motor neurons.

ACE-2223, Acelot's small molecule, is specifically designed to target misfolded forms of TDP-43 that contribute to ALS pathology. By disrupting the diseased form of TDP-43, the drug aims to restore the protein's healthy form and function, ultimately improving cellular health and motor neuron survival. Acelot's innovative approach includes de novo drug design and leveraging AI tools to create promising solutions for devastating diseases.

The company's team comprises experts in rigorous science and efficient development, collaborating with renowned scientists to accelerate the delivery of potential treatment options. Acelot's pursuit extends beyond ALS, exploring applications in various neurodegenerative diseases like fronto-temporal dementia, Alzheimer's disease, and others. With a focus on cutting-edge research and drug development, Acelot strives to make a meaningful impact in the field of neurodegenerative diseases.

Generated from the website content